Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Immunogenicity Objective ? To evaluate the immunogenicity of two doses of rMenB+OMV NZ in subjects with increased risk of meningococcal disease because of complement deficiency or asplenia and in healthy age-matched subjects, at 1 month after the second vaccination. Safety Objective ? To assess the safety and tolerability of two doses of rMenB+OMV NZ in subjects with increased risk of meningococcal disease because of complement deficiency or asplenia and in healthy age-matched subjects. Evaluar la inmunogenicidad de dos dosis de rMenB+OMV NZ en sujetos con riesgo elevado de padecer una enfermedad meningocócica a causa de una deficiencia de complemento o asplenia y en sujetos sanos agrupados por edad, un mes después de la segunda vacunación Evaluar seguridad
Critère d'inclusion
- Meningococcal Group B disease